Amylin/Takeda combo the latest casualty in obesity war of attrition
05 August 2011
Ian Haydock
Please Login to read the full article.
05 August 2011
Ian Haydock
Please Login to read the full article.
RELATED CONTENT
NEWS
- Sanofi, Pfizer, Takeda, or Roche fit partner profile for Amylin's exenatide
- Private equity player Celtic bankrolls new Swiss antibody-drug conjugate company
- NICE confirms earlier draft recommendation for Lilly's GLP1-agonist
- Ember burns as Third Rock's $34m launches 'brown fat' approach in obesity/diabetes
COMMENT
Other Informa Comment
EVENTS
Today
The Rembrandt Hotel, London
07 June 2012
The Rembrandt Hotel, London
18 June 2012
Boston Convention & Exhibition Center, Boston, MA
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
